Novel ATP-competitive Akt inhibitor afuresertib suppresses the proliferation of malignant pleural mesothelioma cells

Masayuki Yamaji1,2,a, Akinobu Ota2,a, Md Wahiduzzaman2, Sivasundaram Karnan2, Toshinori Hyodo2, Hiroyuki Konishi2, Shinobu Tsukui2, Yoshihata Hosokawa2 & Masayuki Haniuda1

1Division of Chest Surgery, Department of Surgery, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan
2Department of Biochemistry, Aichi Medical University School of Medicine, Nagakute, Aichi 480-1195, Japan

Keywords
Afuresertib, Akt inhibitor, cancer therapy, Mesothelioma

Abstract
Malignant pleural mesothelioma (MPM), an asbestos-related occupational disease, is an aggressive and incurable tumor of the thoracic cavity. Despite recent advances in MPM treatment, overall survival of patients with MPM is very low. Recent studies have implicated that PI3K/Akt signaling is involved in MPM cell survival and development. To investigate the effects of Akt inhibitors on MPM cell survival, we examined the effects of nine selective Akt inhibitors, namely, afuresertib, Akti-1/2, AZD5363, ipatasertib, MK-2206, perifosine, PHT-427, and TAC10, on six MPM cell lines, namely, ACC-MESO-4, Y-MESO-8A, MSTO-211H, NCI-H28, NCI-H290, and NCI-H2052, and a normal mesothelial cell line MeT-5A. Comparison of IC50 values of the Akt inhibitors showed that afuresertib, an ATP-competitive specific Akt inhibitor, exerted tumor-specific effects on MPM cells. Afuresertib significantly increased caspase-3 and caspase-7 activities and apoptotic cell number among ACC-MESO-4 and MSTO-211H cells. Moreover, afuresertib strongly arrested the cell cycle in the G1 phase. Western blotting analysis showed that afuresertib increased the expression of p21WAF1/CIP1 and decreased the phosphorylation of Akt substrates, including GSK-3β and FOXO family proteins. These results suggest that afuresertib-induced p21 expression promotes G1 phase arrest by inducing FOXO activity. Furthermore, afuresertib significantly enhanced cisplatin-induced cytotoxicity. Interestingly, results of gene set enrichment analysis showed that afuresertib modulated the expression of E2F1 and MYC, which are associated with fibroblast core serum response. Together, these results suggest that afuresertib is a useful anticancer drug for treating patients with MPM.

Introduction
Malignant pleural mesothelioma (MPM) is an incurable thoracic malignancy, with a gradually increasing incidence worldwide because of asbestos exposure [1, 2]. Despite the availability of different options for treating patients with MPM, including surgery, radiotherapy, and chemotherapy, median survival of these patients ranges between 6 and 9 months after diagnosis, indicating poor prognosis [3]. Recent studies implicated that several oncogenic somatic events are involved in MPM development [4, 5]. Whole-exon sequencing identified frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in patients with MPM [4]. Activation of Hippo-Yes-associated protein/ transcripitional coactivator with PDZ-binding motif (YAP/TAZ) signaling plays an important role in MPM cell proliferation [5]. Although several molecules associated with cancer development have been identified, an efficient molecular targeting therapy for treating patients with MPM remains to be developed. Therefore, effective clinical approaches are required for treating MPM.

Akt (protein kinase B) is a master regulator of cell survival in response to growth factors [6, 7]. In human cancers, Akt plays a pivotal role in cell growth, apoptosis inhibition, protein synthesis, and glucose and fatty acid metabolism by phosphorylating its substrates, including CDK2, FOXO, GSK-3beta, S6 kinase, and mTOR [8]. These processes are frequently activated in various solid...
and hematologic malignancies. In addition, Akt phosphorylates YAP/TAZ, which induces mesothelioma cell proliferation by upregulating the expression of cell cycle-promoting genes [5] and suppressing the expression of proapoptotic BAX [9]. Akt activation induces resistance to trastuzumab [10–12], hormonal treatment for breast [13–15] and prostate cancers [16–18], and chemotherapy [19–21]. Thus, accumulating evidence implicate that Akt signaling is one of the most promising targets for cancer therapy.

To date, several compounds have been shown to inhibit the molecular action of Akt and tumor cell growth [8]. Recent studies clinically evaluated perifosine and afuresertib for treating patients with relapsed myeloma [22, 23]. In addition, GDC-0068 is currently in preclinical development for treating triple-negative breast cancer [24]. Because inhibition of Akt signaling is an attractive target for cancer therapy, it is interesting to examine the effects of Akt inhibitors on MPM cell growth.

In this study, we found that afuresertib preferentially inhibited the proliferation of, significantly induced the apoptosis of, and enhanced cisplatin-induced cytotoxicity against MPM cells. Moreover, we determined molecular mechanism underlying the antitumor effects of afuresertib.

**Materials and Methods**

**Reagents**

RPMI1640 medium and penicillin-streptomycin were purchased from Wako Pure Chemical Industries, Ltd (Osaka, Japan). FBS was obtained from Nichirei Biosciences Inc. (Tokyo, Japan). MTT was obtained from Sigma-Aldrich (St. Louis, MO). Akt inhibitors afuresertib, Akti-1/2, AZD5363, GS690693, ipatasertib (GDC-0068), MK-2206, perifosine, PHT-427, and TIC10 and PDPK1 inhibitor OSU-03012 were obtained from Selleck Chemicals (Houston, TX). Propidium iodide (PI) was obtained from Merck Millipore (Billerica, MA). Annexin V (AxV)–FITC was obtained from MBL (Nagoya, Japan). All antibodies used in this study were purchased from Cell Signaling Technology Inc. (Beverly, MA).

**Cell culture**

Six MPM cell lines, namely, ACC-MESO-4, MSTO-211H, NCI-H2052, NCI-H28, NCI-H290, and Y-MESO-8A, and a normal mesothelial cell line MeT-5A were kindly provided by Dr. Y. Sekido, Division of Molecular Oncology, Aichi Cancer Center Research Institute. The cell lines were maintained in RPMI1640 medium supplemented with 10% heat-inactivated FBS and penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO₂. The cells were detached from 90-mm dishes using trypsin and were seeded in 96-, 24-, 12-, or 6-well plates for experimental purposes.

**Cell viability assay**

MPM cells were seeded in 96-well plates (cell density, 2.5 × 10³ cells/well) and were incubated for 24 h at 37°C. Next, the cells were incubated in a medium containing indicated concentrations of Akt inhibitors for 72 h. Next, MTT solution was added to each well, and the cells were incubated for 4 h. Finally, the cells were incubated overnight with lysis buffer (10% SDS in 0.01 mol/L hydrogen chloride). Absorbance was measured at 550 nm using SpectraMAX M5 spectrophotometer (Molecular Devices, Sunnyvale, CA).

**Apoptosis assay**

Apoptosis was evaluated by performing AxV–FITC/PI double staining-based FACS analysis, as described previously [25]. Briefly, ACC-MESO-4 and MSTO-211H cells were seeded in six-well plates (cell density, 1 × 10⁵ cells/well) and were incubated for 24 h at 37°C. Next, the cells were incubated with indicated concentrations of afuresertib, followed by incubation with AxV–FITC and PI (10 μg/mL) for 15 min at room temperature. Fluorescence intensities were determined by performing FACS with FACSCantoII (BD, Franklin Lakes, NJ).

**Cell cycle analysis**

Cell cycle was evaluated by performing PI-staining-based FACS analysis, as described previously [26]. ACC-MESO-4 and MSTO-211H cells were seeded in a six-well culture plate (cell density, 1 × 10⁵ cells/well) and were incubated for 24 h. Next, the cells were incubated with the indicated concentrations of afuresertib for 24 h. For FACS analysis, the cells were detached using trypsin after 24 h of serum treatment and were fixed overnight in ice-cold 70% ethanol. After fixation, the cells were treated with RNase A (100 μg/mL) and stained with PI (10 μg/mL). The percentages of cells in the sub-G₁, G₁, S, and G₂-M phases of the cell cycle were measured using FlowJo software (Tree Star Inc.; Ashland, OR USA).

**Cell confluence proliferation assay**

Cell confluence proliferation assay was performed using Incucyte ZOOM® Live-Cell Imaging System (Essen Bioscience, Ann Arbor, MI), according to the manufacture’s instruction. Briefly, ACC-MESO-4 and MSTO-211H
Afuresertib Decreases the Survival of MPM Cells

M. Yamaji et al.

Copyright © 2017 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Results

Phosphorylated forms of Akt increase in MPM cells

To investigate Akt activation in MPM cells, we first examined the phosphorylation level of Akt (Thr308 and Ser473) in the six MPM cell lines ACC-MESO-4, MSTO-211H, NCI-H2052, NCI-H28, NCI-H290, and Y-MESO-8A and the normal mesothelial cell line MeT-5A. Western blotting analysis showed that the phosphorylation of Akt (Thr308 and Ser473) increased in the MPM cell lines (Fig. 1A and B), indicating that Akt was frequently activated in MPM cells. We also examined the expression or phosphorylation level of upstream molecules in Akt signaling, including PDPK1, PI3K catalytic subunit p110α, and PI3K regulatory subunit p85. We found that PI3K/p110α expression increased in the MPM cell lines (Fig. 1A). In contrast, the expression and phosphorylation levels of PI3K/p85, which negatively regulates the catalytic activity of p110α [28], were negligible in the MPM cell lines except for NCI-H28, whereas only total PI3K/p85 was detected in normal mesothelial cell line MeT-5A (Fig. 1A). In addition, western blotting analysis clearly detected the phosphorylation level of PDPK1 in all the MPM cell lines and the normal mesothelial cell line (Fig. 1A). Together, these results suggest that PI3K/Akt signaling pathway is highly activated in MPM cells.

Afuresertib, a potent Akt inhibitor, exhibits favorable tumor-suppressive effects on MPM cells

To investigate the involvement of Akt in MPM cell growth, we examined whether Akt inhibitors afuresertib, Akti-1/2, AZD5363, GSK690693, ipatasertib (GDC-0068), MK-2206, perifosine, PHT-427, and TIC10 affected the survival of the MPM cell lines and the normal mesothelial cell line. Target molecules, mechanisms of action, and structural features of the inhibitors are summarized in Table 1. Results of the MTT assay showed that treatment with all the Akt inhibitors suppressed cell viability in a dose-dependent manner (Fig. 1C), suggesting that inhibition of Akt activity suppressed MPM cell growth. To determine the tumor specificity of the nine Akt inhibitors, we examined the IC50 values of these inhibitors against MPM cells. The IC50 values of the Akt inhibitors are summarized in Table 2 and Figure 3. Notably, we found that the IC50 values of both afuresertib and GDC-0068 against all the MPM cell lines were lower than those against the normal mesothelial cell line MeT-5A (Fig. 2), suggesting that these inhibitors exerted tumor-specific antiproliferative effect on MPM cells.
Afuresertib Decreases the Survival of MPM Cells

M. Yamaji et al.

Afuresertib decreases the survival of MPM cells. Akt is recruited to the plasma membrane by phosphatidylinositol (3,4,5) trisphosphates (PIP3), which is produced by PI3K. Akt is then phosphorylated at T308 and S473 by phosphoinositide-dependent kinase-1 (PDPK1) and mTORC2, respectively [29]. Therefore, we examined the effect of PI3K inhibitor PF04691502 and PDPK1 inhibitor OSU-03012 on the survival of MPM cells by performing the MTT assay. We found that both PF04691502 and OSU-03012 suppressed MPM cell survival in a dose-dependent manner (Fig. S1A). Moreover, we found that the IC50 values of PF04691502 but not OSU-03012 against all the MPM cell lines were lower than those against the normal mesothelial cell line MeT-5A (Fig. S1B).

Afuresertib suppresses clonogenic activity and induces apoptosis

Because the IC50 values for afuresertib against the MPM cell lines were approximately 50% lower than those of GDC-0068, we used afuresertib for performing subsequent experiments. We examined the tumor-suppressive effect of afuresertib on ACC-MESO-4, MSTO-211H, and NCI-H2052 cells. Afuresertib significantly inhibited colony formation by ACC-MESO-4, MSTO-211H, and NCI-H2052 cells (P < 0.005 for ACC-MESO-4 and MSTO-211H and P < 0.05 for NCI-H2052; Fig. 3A). The Akt inhibitor perifosine suppresses MPM cell growth [30]. Therefore, we examined the effect of afuresertib and perifosine on the clonogenicity. Afuresertib but not perifosine significantly decreased the number of colonies formed by normal mesothelial MeT-5A cells (Figs. S2 A and B). In addition, perifosine but not afuresertib significantly decreased the number of colonies formed by normal mesothelial cell lines (Figs. S2 A and B). These results strongly suggest that afuresertib exerts favorable tumor-suppressive effects against MPM cells. We further examined the effect of afuresertib on apoptosis in ACC-MESO-4 and MSTO-211H cells. The percentages of Axx+/PI+ cells significantly increased in both ACC-MESO-4 and MSTO-211H cells after 48 h of afuresertib treatment (Fig. 3B). In addition, afuresertib significantly increased caspase-3 and caspase-7 activities in ACC-MESO-4 cells (Fig. 3C).
### Table 1. Summary of AKT inhibitors used in this study.

| Inhibitors         | Target molecules       | Mechanism of action                  | Structural feature                      |
|--------------------|------------------------|--------------------------------------|-----------------------------------------|
| Afuresertib        | AKT1, AKT2, AKT3       | catalytic, ATP-competitive inhibitor  | thiophenecarboxamide derivatives        |
| Akti-1/2           | AKT1, AKT2             | allosteric inhibitor                 |                                         |
| AZD5363            | AKT, PKA, mTOR         | catalytic, ATP-competitive inhibitor  | 2,3-diphenylquinoxaline core heterocyclic rings |
| GSK690693          | AKT                    | catalytic, ATP-competitive inhibitor  | Aminofurazan                            |
| Ipatasertib        | AKT                    | catalytic, ATP-competitive inhibitor  | heterocyclic rings                      |
| MK-2206            | AKT                    | allosteric inhibitor                 | 2,3-diphenylquinoxaline analogue        |
| OSU-03012 (AR-12)  | PDK-1                  | catalytic, ATP-competitive inhibitor  | celecoxib (COX-2 inhibitor)-derived small-molecule |
| Perifosine         | AKT                    | allosteric inhibitor                 | alkylphospholipid                       |
| PF-04691502        | P3K                    | catalytic, ATP-competitive inhibitor  | 4-methylpyridopyrimidinone derivatives   |
| PHT-427            | AKT                    | allosteric inhibitor                 | sulfonamide derivative                  |
| TIC10              | AKT, ERK               | unknown                              | imidazo[1,2-a]pyrido[4,3-d] pyrimidine derivative |
Moreover, afuresertib slightly increased caspase-3 and caspase-7 activities in MSTO-211H cells (Fig. 3C). Similarly, results of western blotting analysis showed that afuresertib increased the levels of proapoptotic molecules, including BIM and BAX, and cleaved caspase-3 in ACC-MESO-4 cells (Fig. 3D). These results suggest that afuresertib-induced inhibition of MPM cell proliferation is associated with apoptosis induction.
Inhibition of Akt activity was reported to distribute cell cycle properties [31]. Therefore, we examined the effect of afuresertib on cell cycle status by performing PI-staining-based FACS analysis. Afuresertib dramatically increased the population of cells in the G₀/G₁ phase and decreased the population of cells in the S and G₂/M phases of the cell cycle (Fig. 4A). Results of the cell confluence proliferation assay showed that afuresertib suppressed cell confluence in a dose-dependent manner (Fig. S3), suggesting that afuresertib arrested cell cycle in the G₀ phase. We next investigated the effect of afuresertib on the expression and/or phosphorylation levels of downstream molecules, including Akt substrates and cell cycle regulators. Phosphorylation levels of Akt substrates GSK3β (Ser9/21), mTOR (Ser2448), and p70 (Thr389) decreased after afuresertib treatment (Fig. 4C). Interestingly, phosphorylation level of YAP, a transcriptional factor in the Hippo signaling pathway, decreased after afuresertib treatment (Fig. 4C). Moreover, phosphorylation levels of Akt (Thr308 and Ser473) increased after afuresertib treatment (Fig. 4C). In addition, afuresertib decreased the levels of E2F1 and CDK4 and phosphorylation level of CDK2 and increased the level of p21WAF1/CIP1, a cell cycle regulator in the G₁ phase (Fig. 4D). p53 is a well-known inducer of p21WAF1/CIP1. In this study, we did not observe any increase in the phosphorylation levels of p53 (Ser15 and Ser20) (Fig. 4D). FOXO1, an Akt substrate, potentiates p21 expression after undergoing dephosphorylation. Therefore, we examined changes in the phosphorylation level of FOXO1. As expected, we observed that the phosphorylation level of FOXO1.
FOXO1 (Thr24 and Ser256) decreased after afuresertib treatment (Fig. 4E). The effect of afuresertib on the migration of MPM cells was determined by performing the scratching assay with ACC-MESO-4 and MSTO-211H cells. We found that afuresertib (5 μmol/L) clearly suppressed the migration of MPM cells (Figure S4). These results strongly suggest that afuresertib inhibits the growth of MPM cell and decreases the phosphorylation of several direct and/or indirect Akt substrates.

**Afuresertib and cisplatin treatment cooperatively suppress cell survival and induce apoptosis**

Cisplatin (CDDP) is one of the most frequently used anticancer drugs for MPM treatment [32]. Therefore, we examined whether afuresertib affected the cytotoxic effect of CDDP. Results of the MTT assay showed that afuresertib and CDDP combination treatment significantly suppressed the viability of both ACC-MESO-4 and MSTO-211H cells compared with afuresertib or CDDP monotherapy (Fig. 5A). This novel finding prompted us to examine the effect of afuresertib and CDDP combination treatment on apoptosis induction. As expected, the combination treatment significantly induced apoptosis (Fig. 5B), indicating that afuresertib-induced Akt inhibition enhanced the cytotoxic effect of CDDP on MPM cells. We also examined whether afuresertib affected the cytotoxic effect of pemetrexed on MPM cells. Results of the MTT assay showed that pemetrexed treatment decreased the survival of MSTO-211H cells but not of ACC-MESO-4 cells (Fig. S5A). Therefore, we examined the effect of afuresertib and pemetrexed combination treatment on apoptosis induction in MSTO-211H cells. Results of flow
cytometry analysis showed that afuresertib significantly enhanced pemetrexed-induced apoptosis in ACC-MESO-4 cells (Fig. S5B).

Afuresertib downregulates the expression of a subset of genes with oncogenic signatures

To clarify the effect of afuresertib on gene expression in MPM cells, we conducted a comprehensive cDNA microarray analysis. Heatmap analysis showed similar gene expression patterns of afuresertib-treated MSTO-211H and ACC-MESO-4 cells (Fig. 6A). Fold change analysis showed that afuresertib upregulated the expression of 262 genes by >2.0 fold and downregulates the expression of 219 genes by <0.5 fold compared with that in untreated cells (Tables S2 and Table S3). PANTHER classification analysis showed that 43.3% of the downregulated genes encoded nucleic acid-binding protein (Fig. 6B). Interestingly, we found that 76.7% of the downregulated genes encoding nucleic acid-binding protein are further classified into a protein class of DNA binding protein (data not shown), suggesting that afuresertib may affect DNA-protein interaction in MPM cells. Therefore, we performed gene set enrichment analysis (GSEA) to investigate whether the expression of a specific set of oncogenesis-associated genes was significantly different between afuresertib-treated and untreated MPM cells. Result of GSEA of genes with oncogenic signatures showed significant inactivation of Akt signaling-associated genes (SFRP2, FANK1, and GAS1), serum-responsive genes (e.g., ZWINT, UHRF1, and CDC7), E2F1-induced genes (e.g. CHAF1B, UCK2, and TOP2A),
MYC-induced genes (e.g., \textit{PIGW}, \textit{UTP15}, and \textit{SLC25A22}), and mTOR-related genes (e.g., \textit{ING4}, \textit{HBP1}, and \textit{KIAA0355}) (Fig. 6C). We also found that afuresertib significantly decreased the expression of cell cycle-dependent kinase 1 gene (\textit{CDK-1}), \textit{CDK-2}, \textit{E2F1}, and insulin-like growth factor-binding protein 3 gene (\textit{IGFBP3}) but not of \textit{GAPDH} in MPM cells (Fig. S6). GSEA using Kyoto Encyclopedia of Genes and Genomes database also showed significant inactivation of genes associated with spliceosome-, DNA replication-, and cell cycle-related signaling (Fig. S7). These results strongly suggest that afuresertib suppresses MPM cell proliferation by modulating the expression genes associated with oncogenic signaling. Collectively, our results suggest that afuresertib exerts promising tumor-suppressive effect on MPM cells.

**Discussion**

MPM is associated with an increasing incidence rate in industrially advanced countries. Despite advancements in medical techniques for treating MPM, it is still a highly incurable disease. Therefore, new molecular targeting therapies are warranted to effectively treat patients with MPM. In this study, we examined the effects of a panel of Akt inhibitors on the survivals of MPM cell lines and an immortalized normal mesothelial cell line and found that afuresertib exerts favorable tumor-suppressive effects. We also found that afuresertib decreased the phosphorylation and/or total protein levels of Akt substrates and/or cell cycle-related molecules. Moreover, we found that afuresertib significantly downregulates the expression of genes with oncogenic signatures.

Akt inhibitors are classified into two groups and are currently being developing for clinical use [33]. One group of Akt inhibitors includes catalytic, ATP-competitive inhibitor (such as afuresertib) that preferentially target active kinases. Another group of AKT inhibitors includes allosteric inhibitor (such as perifosine) that binds to the N-terminal pleckstrin homology domain of Akt. These inhibitors induce conformational changes in Akt that prevents its membrane localization and subsequent activation [34]. Recently, Pinton et al. reported that the allosteric Akt inhibitor perifosine suppressed MPM cell growth by inhibiting EGFR/MET-Akt signaling axis [30]. In this study, we found that the catalytic, ATP-competitive Akt inhibitor afuresertib suppressed the growth and clonogenic
activity of MPM cells in a dose-dependent manner. Similar results were obtained with another catalytic, ATP-competitive Akt inhibitor ipatasertib. Analysis of $IC_{50}$ values indicated that the dose of afuresertib required for suppressing MPM cell growth was lower than that of perifosine. Our observation that the average of $IC_{50}$ value of afuresertib against MPM cell lines was lower than that against MeT-5A strongly suggests that afuresertib preferentially affects MPM cell growth compared with perifosine.

PI3K is a well-known upstream molecule of Akt and plays an important role in activating Akt [6]. In this study, we found that the catalytic, ATP-competitive PI3K inhibitor PF04691502 dose-dependently suppressed MPM cell survival, with $IC_{50}$ values similar to those of afuresertib. This result indicates that PI3K-Akt signaling performs a tumorigenic role in MPM cells.

ATP-competitive Akt inhibitors, including A-443654 and GSK GSK690693, induce paradoxical hyperphosphorylation of Akt at its two regulatory sites Thr308 and Ser473 [35].

Figure 6. Gene expression analysis. MSTO-211H and ACC-MESO-4 cells were incubated with or without afuresertib (10 μmol/L) for 24 h. Next, total RNA was extracted and cDNA microanalysis was performed using SurePrint G3 Human 8 x 60K V3 format (Agilent). (A) Heatmap of the upregulated genes (262 genes; fold change, >2.0) and downregulated genes (219 genes, fold change <0.5) after afuresertib treatment. The heatmap was constructed using normalized values of each sample with Treeview software. A heatmap showing downregulated genes, with the corresponding gene name at the right side, after afuresertib treatment. (B) Gene ontology analyses using the Panther classification system. The upregulated and/or downregulated genes were classified using PANTHER - Gene List Analysis (www.pantherdb.org). (C) GSEA was conducted using GSEA v2.2.4 software and Molecular Signatures Database (Broad Institute). All raw data were formatted and applied to oncogenic signatures (C6). Representative GSEA enrichment plots and corresponding heatmap images of the indicated gene sets in 10 μmol/L afuresertib-treated and untreated cells, respectively, are shown. Genes contributing to enrichment are shown in rows, and the sample is shown in one column on the heatmap. Expression level is represented as a gradient from high (red) to low (blue). FDR, false discovery rate; NES, normalized enrichment score.
In this study, we found that afuresertib enhanced the phosphorylation of Akt at Thr308 and Ser473, which is consistent with that observed using other catalytic, ATP-competitive Akt inhibitors, including GDC-0068 [33].

Results of gene expression profiling performed in this study showed that afuresertib significantly suppresses onco-genic gene expression related to serum response, E2F1, MYC, mTOR, as well as Akt. This result suggests that afuresertib-induced hyperphosphorylation does not activate Akt-mediated signaling. We also found that afuresertib increased the expression of gene sets associated with inositol phosphate and/or amino acid metabolisms, including branched chain amino acids (BCAAs) and tryptophan metabolism, suggesting that these metabolic pathways are alternatively used to supply cellular energy after Akt inhibition in MPM cells. Therefore, it would be interesting to examine whether inhibition of inositol phosphate and/or BCAA metabolic pathways enhances afuresertib-induced suppression in MPM cells.

Akt activation induces resistance to chemotherapy [19, 20]. Our finding that afuresertib enhanced CDDP-induced tumor suppression strongly suggests that afuresertib prolongs the chemosensitivity of MPM cells and/or overcomes chemo resistance to CDDP in patients with MPM. Pinton et al. reported that the combination of perifosine with CDDP but not with pemetrexed exerted synergistic tumor-suppressive effect on MPM cells [30].

In conclusion, this study is the first to show that afuresertib decreased the survival of MPM cells by inhibiting Akt. Our results suggest that the catalytic, ATP-competitive Akt inhibitor afuresertib preferentially inhibits MPM cell growth compared with allosteric inhibitors such as perifosine. It would be interesting to investigate molecular mechanism through which afuresertib exerts tumor-specific cytotoxicity. Our novel finding that afuresertib enhanced CDDP-induced cytotoxic effects provides an attractive option of using afuresertib and cisplatin combination therapy for treating MPM. Because our data were mainly obtained from in vitro studies, it is necessary to assess the anticancer activity of afuresertib in vivo, for example, by establishing xenograft models. Moreover, further studies are required to develop novel molecular targeting therapies for MPM treatment.

Conflict of Interest
The authors declare that they do not have any conflicts of interest related to this study.

References
1. Robinson, B. W., and R. A. Lake. 2005. Advances in malignant mesothelioma. New Engl. J. Med. 353:1591–1603.
2. Campbell, N. P., and H. L. Kindler. 2011. Update on malignant pleural mesothelioma. Semin. Respir. Crit. Care Med. 32:102–110.
3. Milano, M. T., and H. Zhang. 2010. Malignant pleural mesothelioma: a population-based study of survival. J. Thorac. Oncol. 5:1841–1848.
4. Guo, G., J. Chmielecki, C. Goparaju, A. Heguy, I. Dolgalev, M. Carbone, et al. 2015. Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma. Can. Res. 75:264–269.

5. Mizuno, T., H. Murakami, M. Fujii, F. Ishiguro, I. Tanaka, Y. Kondo, et al. 2012. YAP induces malignant mesothelioma cell proliferation by upregulating transcription of cell cycle-promoting genes. Oncogene 31:5117–5122.

6. Vivanco, I., and C. L. Sawyers. 2002. The phosphatidylinositol 3-kinase Akt pathway in human cancer. Nat. Rev. Cancer 2:489–501.

7. Testa, J. R., and P. N. Tsichlis. 2005. Akt signaling in normal and malignant cells. Oncogene 24:7391–7393.

8. Nitulescu, G. M., D. Margina, P. Juzenas, Q. Peng, O. T. Olaru, E. Saloustros, et al. 2016. Akt inhibitors in cancer treatment: the long journey from drug discovery to clinical use (Review). Int. J. Oncol. 48:869–885.

9. Basu, S., N. F. Totty, M. S. Irwin, M. Sudol, and J. Downward. 2003. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol. Cell 11:11–23.

10. Davies, B. R., H. Greenwood, P. Dudley, C. Crafter, D. H. Yu, J. Zhang, et al. 2012. Preclinical pharmacology of AZD5363, an inhibitor of Akt: pharmacodynamics, antitumor activity, and correlation of monotherapy activity with genetic background. Mol. Cancer Ther. 11:873–887.

11. Nagata, Y., K. H. Lan, X. Zhou, M. Tan, F. J. Esteva, A. A. Sahin, et al. 2004. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6:117–127.

12. Berns, K., H. M. Horlings, B. T. Hennessy, M. Madireddy, E. M. Hijmans, K. Beelen, et al. 2007. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402.

13. Miller, T. W., B. T. Hennessy, A. M. Gonzalez-Angulo, E. M. Fox, G. B. Mills, H. Chen, et al. 2010. Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer. J. Clin. Invest. 120:2406–2413.

14. Kirkegaard, T., C. J. Witton, L. M. McGlynn, S. M. Tovey, B. Dunne, A. Lyon, et al. 2005. Akt activation predicts outcome in breast cancer patients treated with tamoxifen. J. Pathol. 207:139–146.

15. Musgrove, E. A., and R. L. Sutherland. 2009. Biological determinants of endocrine resistance in breast cancer. Nat. Rev. Cancer 9:631–643.

16. Murillo, H., H. Huang, L. J. Schmidt, D. I. Smith, and D. J. Tindall. 2001. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142:4795–4805.

17. Li, B., A. Sun, H. Youn, Y. Hong, P. F. Terranova, J. B. Thrasher, et al. 2007. Conditional Akt activation promotes androgen-independent progression of prostate cancer. Carcinogenesis 28:572–583.

18. Jiao, J., S. Wang, R. Qiao, I. Vivanco, P. A. Watson, C. L. Sawyers, et al. 2007. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development. Can. Res. 67:6083–6091.

19. Wendel, H. G., E. de Stanchina, J. S. Fridman, A. Malina, S. Ray, S. Kogan, et al. 2004. Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature 428:332–337.

20. Kim, D., H. C. Dan, S. Park, L. Yang, Q. Liu, S. Kaneko, et al. 2005. Akt/PKB signaling mechanisms in cancer and chemoresistance. Front Biosci. 10:975–987.

21. Pei, H., L. Li, B. L. Fridley, G. D. Jenkins, K. R. Kalari, W. Lingle, et al. 2009. FKBPS1 affects cancer cell response to chemotherapy by negatively regulating Akt. Cancer Cell 16:259–266.

22. Jakubowiak, A. J., P. G. Richardson, T. Zimmerman, M. Alsina, J. L. Kaufman, M. Kandarpa, et al. 2012. Perifosine plus lenalidomide and dexamethasone in relapsed and relapsed/refractory multiple myeloma: a phase I multiple myeloma research consortium study. Br. J. Haematol. 158:472–480.

23. Tolcher, A. W., A. Patnaik, K. P. Papadopoulos, D. W. Rasco, C. R. Becerra, A. J. Allred, et al. 2015. Phase I study of the MEK inhibitor trametinib in combination with the Akt inhibitor afuresertib in patients with solid tumors and multiple myeloma. Cancer Chemother. Pharmacol. 75:183–189.

24. Lehmann, B. D., J. A. Pietenpol, and A. R. Tan. 2015. Triple-negative breast cancer: molecular subtypes and new targets for therapy. Am. Soc. Clin. Oncol. Educ. Book 2015:e31–e39.

25. Nakao, K., T. Ota, T. Ono, S. Karnan, H. Konishi, A. Furuhashi, et al. 2014. Combined arsenic trioxide-cisplatin treatment enhances apoptosis in oral squamous cell carcinoma cells. Cell. Oncol. (Dordr.) 37:119–129.

26. Ota, A., H. Nakao, Y. Sawada, S. Karnan, M. Wahiduzzaman, H. Konishi, et al. 2017. Delta40p53 suppresses tumor cell proliferation and induces cellular senescence in hepatocellular carcinoma cells. J. Cell Sci. 130:614–625.

27. Takahashi, M., A. Ota, S. Karnan, E. Hossain, Y. Konishi, L. Damdindorj, et al. 2013. Arsenic trioxide prevents nitric oxide production in lipopolysaccharide-stimulated RAW 264.7 by inhibiting a TRIF-dependent pathway. Cancer Sci. 104:165–170.
Afuresertib Decreases the Survival of MPM Cells

M. Yamaji et al.

28. Luo, J., and L. C. Cantley. 2005. The negative regulation of phosphoinositide 3-kinase signaling by p85 and it’s implication in cancer. Cell Cycle 4:1309–1312.

29. Vadakonda, L., A. Dash, M. Pasupuleti, K. Anil Kumar, and P. Reddanna. 2013. The paradox of Akt-mTOR interactions. Front. Oncol. 3:365.

30. Pinton, G., A. G. Manente, G. Angeli, L. Mutti, and L. Moro. 2012. Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma. PLoS ONE 7:e36856.

31. Chang, F., J. T. Lee, P. M. Navolanic, L. S. Steelman, J. G. Shelton, W. L. Blalock, et al. 2003. Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603.

32. Vogelzang, N. J., J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, et al. 2003. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J. Clin. Oncol. 21:2636–2644.

33. Yan, Y., V. Serra, L. Prudkin, M. Scaltriti, S. Murli, O. Rodriguez, et al. 2013. Evaluation and clinical analyses of downstream targets of the Akt inhibitor GDC-0068. Clin. Cancer Res. 19:6976–6986.

34. Lindsley, C. W., Z. Zhao, W. H. Leister, R. G. Robinson, S. F. Barnett, D. Deleo-Jones, et al. 2005. Allosteric Akt (PKB) inhibitors: discovery and SAR of isoform selective inhibitors. Bioorg. Med. Chem. Lett. 15:761–764.

35. Okuzumi, T., D. Fiedler, C. Zhang, D. C. Gray, B. Aizenstein, R. Hoffman, et al. 2009. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5:484–493.

36. Hakiri, S., H. Osada, F. Ishiguro, H. Murakami, Y. Murakami-Tonami, K. Yokoi, et al. 2015. Functional differences between wild-type and mutant-type BRCA1-associated protein 1 tumor suppressor against malignant mesothelioma cells. Cancer Sci. 106:990–999.

37. Ke, Y., R. R. Reddel, B. I. Gerwin, H. K. Reddel, A. N. Somers, M. G. McMenamin, et al. 1989. Establishment of a human in vitro mesothelial cell model system for investigating mechanisms of asbestos-induced mesothelioma. Am. J. Pathol. 134:979–991.

Supporting Information

Additional supporting information may be found in the online version of this article:

Figure S1. The effect of specific PI3K (PF-04691502) or PDPK1 (OSU-03012) inhibitor on cell survival in MPM cell lines.

Figure S2. The comparison of antitumor effect of afuresertib and perifosine in MPM cell lines (MSTO-211H and ACC-MESO-4) and normal mesothelium cell line (MeT-5A).

Figure S3. Cell confluence proliferation assay.

Figure S4. Scratching assay. ACC-MESO-4 (A) and MSTO-211H (B) cells were seeded in 24-well plates (1 x 105cells/well) and incubated for 24 h at 37°C.

Figure S5. Combinatorial effect of afuresertib with pemetrexed treatment on cell viability and apoptosis.

Figure S6. The results of cDNA microarray analysis.

Figure S7. GSEA analysis with kyotoencyclopedia of genes and genomes (KEGG) gene sets.

Table S1. Antibodies used in this study

Table S2. Downregulated genes after afuresertib treatment in MPM cell lines.

Table S3. Upregulated genes after afuresertib treatment in MPM cell lines.